Radiation Oncology Institute

Recent papers from Radiation Oncology Institute

1. RNF152 promoter methylation and gene expression in oral premalignant lesions and oral squamous cell carcinoma: implications for epigenetic biomarker developmentFrontiers in Oncology · 2026
2. Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphomaHaematologica · 2026
3. Multi-model assessment of yield stability in lentil across multi-environmentsPLoS ONE · 2026
4. Clinical correlates of lipoprotein (a) and apolipoprotein B levels in patients with dyslipidemia and cardiovascular diseaseFrontiers in Cardiovascular Medicine · 2026
5. The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries – For Whom, by Whom and Where?Clinical and Applied Thrombosis/Hemostasis · 2026
6. Izofali Birikma Shaklidagi Metaforalar BadiiyatiSCIENCE TIME · 2026
7. The oncogeriatric transition in Morocco: health-system challenges and strategic priorities in an aging societyFrontiers in Public Health · 2026
8. Epigenetic alterations in cancer metastasis: molecular mechanisms and implications for precision oncologySHILAP Revista de lepidopterología · 2026
9. 22P Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A real-world study from the ARON-2EV projectESMO Open · 2026
10. Role of Anti-GD ₂ Targeted PEG- b -PLGA Nanoparticles in the Treatment of MYCN Driven NeuroblastomaACS Applied Bio Materials · 2026
11. Normal Tissue Complication Probability Modeling for Proton TherapyThe Cancer Journal · 2026
12. Anti-Breast Cancer Effects of Carbon Quantum Dots: In Vivo Angiogenesis and Arginase Co-InhibitionACS Applied Bio Materials · 2026
13. Formal Methods for Early Prediction of Frozen Shoulder severity and recovery: A multicentre prospective studyComputer Methods and Programs in Biomedicine Update · 2026
14. Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer – A Case Report and Experience-Driven StrategySHILAP Revista de lepidopterología · 2026
15. Prognostic Value of Neutrophil-to-Lymphocyte Ratio Across Barcelona Clinic Liver Cancer Stages in Hepatocellular Carcinoma: A Multicenter Retrospective AnalysisBratislavské lekárske listy/Bratislava medical journal · 2026
16. Abstract PS3-04-14: Artificial intelligence (AI) as a decision support tool for practicing oncologists: breast cancer casesClinical Cancer Research · 2026
17. PS5-12-17: A phase 1/2 study of AVZO-023, a next-generation selective cyclin-dependent kinase 4 inhibitor (CDK4i), as a single agent and in combination with AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), and/or endocrine therapy in patients with advanced solid tumorsClinical Cancer Research · 2026
18. Abstract PS4-06-08: A phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as a monotherapy and in combination for patients with advanced solid tumors, including hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer and cyclin E1 (CCNE1)-amplified solid tumors: preliminary safety and efficacy resultsClinical Cancer Research · 2026
19. Abstract PS5-08-25: ReDiscover-2, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)Clinical Cancer Research · 2026
20. Abstract PS1-10-27: Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC)Clinical Cancer Research · 2026